Article Text

PDF
AB0231 Elevation of Serum Matrix Metalloproteinase-3 in A Group of Rheumatoid Arthritis Algerian Patients
  1. D. Fodil1,
  2. S.S. Salah2,
  3. M. Benidir2,
  4. S. Adjabi1,
  5. M.C. Abbadi2,
  6. N. Attal2,
  7. M. Bayou1,
  8. S. Mostefai1
  1. 1Rheumatology, Beni Messous Hospital
  2. 2Immunology, Institute Pasteur of Algeria, Algiers, Algeria

Abstract

Background Matrix metalloproteinase-3 (MMP-3) is a protease induced by inflammatory cytokines in rheumatoid synovium and degrades a number of extracellular matrix components of cartilage and bone. Its central role in rheumatoid joint destruction was especially highlighted from both pathophysiological and clinical studies. In addition, serum MMP-3 level is a clinically useful maker for predicting joint destruction and for disease activity in rheumatoid arthritis (RA).

Objectives The aim of our study is to evaluate the serum matrix metalloproteinase 3 (MMP-3) levels in a group of algerian patients with early and advanced rheumatoid arthritis (RA) compared to healthy subjects.

Methods The study group consisted of 50 patients with RA, including 81.6% women, mean age 45,0±15,0 years, mean duration 4,3±4,2 years, Forty healthy subjects served as a control group (71.4% women, mean age 33,0±13,0 years). Analysis of serum concentrations of MMP-3 was based on a quantitative sandwich ELISA (Aeskulisa DF MMP-3, Aesku.Diagnostics, Wendelsheim, Germany). A cut-off point of 120 ng/ml (men) and 60 ng/ml (women) was used for MMP-3 positive/negative categorization.

Results First of all, 61,3% of patients were rheumatoid factor (RF)-positive and 93,8% anti-CCP positive. MMP-3 is significantly higher in sera of RA patients (Mean value: 175,8±178,2 ng/ml) than in those of control group (Mean value: 23,0±17,8 ng/ml) (p<0,001). The mean value in female and male patients was 161,9±174,7 ng/ml and 237,6±203,8 ng/ml respectively. Further, MMP-3 is higher (188,1±183,7 ng/ml) in sera of patients with early (<2 years duration) than advanced disease (between 3 and 8 years duration) (Mean value: 154,0±153,1 ng/ml) (p<0,05). Interestingly, there is no statistically significant difference between RF-positive patients and RF-negative patients concerning MMP-3 concentration (180,2±196,6 ng/ml vs. 183,3±201,4 ng/ml respectively).

Conclusions In conclusion, patients with RA are characterized by high serum concentrations of MMP-3, particularly in early stages for both female and male affected patients regardless for RF positiviy. Serum concentration of MMP-3 is a useful marker of inflammation in the early stage of RA.

References

  1. Tchetverikov,I. et al. (2003) Matrix metalloproteinases-3, -8, -9 as markers of disease activity and joint damage progression in early rheumatoid arthritis. Ann. Rheum. Dis. 62, 1094-1099.

  2. Shinozaki,M. et al. (2007) Elevation of serum matrix metalloproteinase-3 as a predictive marker for the long-term disability of rheumatoid arthritis patients in a prospective observational cohort IORRA. Mod. Rheumatol. 17, 403-408.

  3. Fiedorczyk,M. et al. (2006) Serum matrix metalloproteinases and tissue inhibitors of metalloproteinases in patients with early rheumatoid arthritis. J. Rheumatol. 33, 1523-1529.

Disclosure of Interest None declared

DOI 10.1136/annrheumdis-2014-eular.6019

Statistics from Altmetric.com

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.